Efficacy and safety of high dose recombinant human thrombopoietin in the treatment of immune thrombocytopenia

Figures & data

Table I. ITP patients’ clinical and laboratory baseline characteristics.

Baseline characteristics	Low-dose group (n = 44)	High-dose group (n = 61)	P value
rhTPO administration dosage (day)	15 000 U	30 000 U	–
Mean weight (range, Kg)	66(50–101)	65.5(46–90)	.793
Mean rhTPO recommended dosage (300 U/Kg/day)	(19830 ± 3427)U	(19652 ± 2837)U	.793
Male/female	26/18	25/36	.067
Mean age (range, years)	55(23–82)	52(17–84)	.266
Median duration of disease (range, M)	29.5(1–320)	30(1–276)	.583
Duration of disease (<3 M/3–12 M/>12 M)	8/6/30	13/9/39	.897
Mean baseline of PLT count (range, x10^9/L)	8.6(1–24)	7.3(1–20)	.254
rhTPO with glucocorticoid (yes/no)	16/28	32/29	.102
Corticodependence(yes/no)	18/22	29/16	.072
Median days of follow-up(range, M)	3(1–13)	2(1–12)	.181
Median bleeding score (range)	1.5(0–8)	1(0–8)	.875

ITP, immune thrombocytopenia; rhTPO, recombinant human thrombopoietin; M, months; PLT, platelet

Figure 1. The variation tendency of platelet count (mean and standard deviation) among the ITP groups of rhTPO dosages.

Table II. Efficacy evaluation of rhTPO in treatment of ITP patients.

Characteristics	Low-dose group (n = 44)	High-dose group (n = 61)	P value
d7
PR	16(36.36%)	30(49.18%)
CR	1(2.27%)	15(24.59%)
OR	17(38.64%)	45(73.77%)
NR	27(61.36%)	16(26.23%)	<.001
d14
PR	13(29.54%)	24(4.00%)
CR	17(38.64%)	31(51.67%)
OR	30(68.18%)	55(91.67%)
NR	14(31.82%)	5(8.33%)	.028
d21
PR	7(16.67%)	12(24.00%)
CR	20(47.62%)	27(54.00%)
OR	27(64.29%)	39(78.00%)
NR	15(35.71%)	11(22.00%)	.309
d28
PR	5(11.90%)	10(2.83%)
CR	14(33.33%)	18(37.50%)
OR	19(45.24%)	28(58.33%)
NR	23(54.76%)	20(41.67%)	.345
Overall efficiency
PR	10(22.73%)	19(31.14%)
CR	21(47.72%)	37(6.66%)
OR	31(7.45%)	56(91.80%)
NR	13(29.55%)	5(8.20%)	.049
Days of rhTPO administration	10(3–14)	7(3–14)	.001
Maintenance(weeks)	3(1–8)	4(2–10)	.260
Effective rate of reusing OR	8/14(57.14%)	11/13(84.62%)	.209
Time of onset (days)	7(3–13)	6(3–14)	.123

Table III. Analysis of efficacy of rhTPO single drug and combined drug.

Characteristics	Low-dose group	High-dose group	P value
Single drug	n = 27	n = 21
PR	8(29.63%)	3(14.29%)
CR	14(51.85%)	16(76.19%)
NR	5(18.52%)	2(9.52%)	.098
Time of onset (days)	7.5(3–13)	6(3–14)	.372
Combination of glucocorticoid	n = 16	n = 32
PR	3(18.75%)	12(37.50%)
CR	6(37.50%)	18(56.25%)
NR	7(43.75%)	2(6.25%)	.038
Time of onset (days)	5(3–13)	6(3–13)	.420
P value	.163	.212
P*value	.759	.596

P* value is the statistic of onset time of single drug and combined glucocorticoid therapy.

Table IV. Response of different doses of rhTPO to disease staging.

Staging of disease	Low-dose group (n = 44)	High-dose group (n = 61)	P value
Newly diagnosed ITP	n = 8	n = 13
PR	1(12.50%)	6(46.15%)
CR	4(5.00%)	7(53.85%)
NR	3(37.50%)	0(.00%)	.378
Persistent ITP	n = 6	n = 9
PR	2(33.33%)	4(44.44%)
CR	3(5.00%)	4(44.44%)
NR	1(16.67%)	1(11.11%)	.949
Chronic ITP	n = 30	n = 39
PR	8(26.67%)	9(23.08%)
CR	13(43.33%)	26(66.66%)
NR	9(3.00%)	4(1.26%)	.029

Table V. Comparison of blood routine between the two groups before and after treatment.

Blood routine index	Low-dose group (n = 44)	High-dose group (n = 61)	P value
Prior treatment
White blood cell count(10^9/L)	8.77 ± 3.94	8.43 ± 3.76	.662
Hemoglobin count(g/L)	125.55 ± 27.19	127.63 ± 3.31	.722
Platelet count(10^9/L)	8.59 ± 6.36	7.27 ± 5.30	.254
Posttreatment
White blood cell count(10^9/L)	8.95 ± 4.85	9.67 ± 3.63	.404
P value	.848	.812
Hemoglobin count(g/L)	124.00 ± 27.08	126.79 ± 23.06	.582
P value	.854	.866
Platelet count(10^9/L)	125.61 ± 119.63	153.35 ± 136.49	.311
P value	<.001	<.001